Acadia Pharmaceuticals Inc (NASDAQ:ACAD) currently has a daily average trading volume of 1.51M but it saw 5797230 shares traded in last market. With a market cap of 3.36B USD, the company’s current market price of $18.35 came rising about 9.95 while comparing to the previous closing price of $16.69. In past 52 weeks, the stock remained buoying in the range of price level as high as $31.82 and as low as $14.15. In the recent trading on the day, stock has struck highest price mark of $17.99 while lowest mark touched by it was $18.805.
Taking a look at 20-day trading activity of Acadia Pharmaceuticals Inc (ACAD) gives us an average price of $17.31, while its current price level is -42.33% below from 52-week high level whereas it is 29.68% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $16.48 while that of 200 days or SMA-200 reads an average of $16.41. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.07% during that period while stretching the period over a month that increases to 4.28%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 61.82 which implies that the stock is in neutral territory.
Morgan Stanley downgraded its recommendation for the stock as a “Equal-Weight” from “Overweight” on August 07, 2024 while assigning a price target range of $28-$20. BMO Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $31.
Over the week, ACAD’s stock price is moving 6.87% up while it is 12.44% when we observe its performance for the past one month. Year-to-date it is -41.39% down and over the past year, the stock is showing a downside performance of -41.39%.
Currently, Acadia Pharmaceuticals Inc’s total number of outstanding shares is 166.35M. Company’s return on investment (ROI) stands at 20.81% and return on equity (ROE) at 27.36%. It has a price to earnings ratio (P/E ratio) of 23.75 while having a 24.12 of forward P/E ratio. Stock’s beta reads 0.40. Stock has a price to book (P/B) ratio of 5.29 while price to sale or P/S ratio amounts to 3.61. Its return on asset (ROA) is 15.97% on average.
